- Previous Close
3.9100 - Open
3.9200 - Bid --
- Ask --
- Day's Range
3.2900 - 3.9800 - 52 Week Range
0.1800 - 8.2000 - Volume
263,871 - Avg. Volume
221,110 - Market Cap (intraday)
7.953M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-44.4000 - Earnings Date Apr 7, 2025 - Apr 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
mainzbiomed.com65
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MYNZ
View MorePerformance Overview: MYNZ
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYNZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYNZ
View MoreValuation Measures
Market Cap
7.95M
Enterprise Value
15.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.95
Price/Book (mrq)
--
Enterprise Value/Revenue
16.62
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-99.24%
Return on Equity (ttm)
-4,333.71%
Revenue (ttm)
917.2k
Net Income Avi to Common (ttm)
-22.51M
Diluted EPS (ttm)
-44.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
977.76k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.58M